復星醫藥(02196.HK)主導抗瘧疾新藥全球多中心三期臨床項目獲330萬美元投資
復星醫藥(02196.HK)公布,由公司主導的抗瘧疾新藥「蒿甲醚苯芴醇阿莫地(口奎)三聯複方製劑」,在非洲和東南亞地區開展的全球多中心三期臨床項目,獲得日本全球衛生創新技術基金(GHIT基金)投資約5億日圓,折合約330萬美元,用於推動該產品研發和上市。
該款候選藥物由復星醫藥、日本丸紅株式會社、牛津大學下屬泰國瑪希隆-牛津熱帶醫學研究中心(MORU)和抗瘧醫藥基金會(MMV)聯合開展。復星醫藥首席執行官文德鏞表示,非常高興能與GHIT基金攜手共同推進抗瘧疾創新藥的臨床研究,加快將該藥物推向市場,積極應對日益嚴峻的瘧原蟲對青蒿素類藥物的耐藥性問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.